Fol. Biol. 2013, 59, 68-75
https://doi.org/10.14712/fb2013059020068
Anticancer Efficiency of Reovirus in Normoxia and Hypoxia
References
1. , E., Green, D. R. (2000) Detection of apoptosis by annexin V labeling. Methods Enzymol, 322, 15-18.
<https://doi.org/10.1016/S0076-6879(00)22004-1>
2. , H. J., Kang, J. S., Byun, J. O., Han, K. S., Kim, D. U., Oh, S. M., Kim, H. M., Chae, S. W., Kim, H. R. (2000) Molecular mechanism of staurosporine-induced apoptosis in osteoblasts. Pharmacol. Res. 42, 373-381.
<https://doi.org/10.1006/phrs.2000.0700>
3. , I. R., Koh, S. S., Min, H. J., Park, E. H., Ratakorn, S., Jhun, B. H., Jeong, S. H., Yoo, Y. H., Youn, H. D., Johnston, R. N., Chung, Y. H. (2010) Down-regulation of HIF-1α by oncolytic reovirus infection independently of VHL and p53. Cancer Gene Ther. 17, 365-372.
<https://doi.org/10.1038/cgt.2009.84>
4. , P., Meintzer, S. M., Widmann, C., Johnson, G. L., Tyler, K. L. (2001) Reovirus infection activates JNK and the JNK-dependent transcription factor c-Jun. J. Virol. 75, 11275-11283.
<https://doi.org/10.1128/JVI.75.23.11275-11283.2001>
5. , M. C., Strong, J. E., Forsyth, P. A., Lee, P. W. (1998) Reovirus therapy of tumors with activated Ras pathway. Science 282, 1332-1334.
<https://doi.org/10.1126/science.282.5392.1332>
6. , J. L., Dermody, T. S. (2002) Virion disassembly is required for apoptosis induced by reovirus. J. Virol. 76, 1632-1641.
<https://doi.org/10.1128/JVI.76.4.1632-1641.2002>
7. , T., Figova, K. (2008) Reolysin – oncolytic virus. Drugs Future 33, 489-495.
<https://doi.org/10.1358/dof.2008.033.06.1215999>
8. , K., Hrabeta, J., Eckschlager, T. (2006) Reovirus – possible therapy of cancer. Neoplasma 53, 457-462.
9. , Y., Kohli, L., Klocke, B. J., Roth, K. A. (2010) Chloroquine-induced autophagic vacuole accumulation and cell death in glioma cells is p53 independent. Neuro. Oncol. 12, 473-481.
10. , S., Rovida, E., Barbetti, V., Cipolleschi, M. G., Olivotto, M., Dello Sbarba, P. (2006) Hypoxia suppresses BCR/Abl and selects imatinib-insensitive progenitors within clonal CML populations. Leukemia 20, 1291-1293.
<https://doi.org/10.1038/sj.leu.2404224>
11. , M., Schlenger, K., Hockel, S., Vaupel, P. (1999) Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res. 59, 4525-4528.
12. , M., Vaupel, P. (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 93, 266-276.
<https://doi.org/10.1093/jnci/93.4.266>
13. , L. E., Bindra, R. S., Glazer, P. M., Harris, A. L. (2007) Hypoxia-induced genetic instability – a calculated mechanism underlying tumor progression. J. Mol. Med. (Berl.) 85, 139-148.
<https://doi.org/10.1007/s00109-006-0133-6>
14. , II, Watson, I. R., Der, S. D., Ohh, M. (2006) Loss of VHL confers hypoxia-inducible factor (HIF)-dependent resistance to vesicular stomatitis virus: role of HIF in antiviral response. J. Virol. 80, 10712-10723.
<https://doi.org/10.1128/JVI.01014-06>
15. , P., Shmulevitz, M., Pan, D., Stoltz, D., Lee, P. W. (2007) Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release. Mol. Ther. 15, 1522-1530.
<https://doi.org/10.1038/sj.mt.6300179>
16. , E., Ratcliffe, P. J. (2004) HIF hydroxylation and cellular oxygen sensing. Biol. Chem. 385, 223-230.
<https://doi.org/10.1515/BC.2004.016>
17. Morris, D. G., Feng, X., Difrancesco, L. M., Fonseca, K., Forsyth, P. A., Paterson, A. H., Coffey, M. C., Thompson, B. (2012) REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors. Invest. New Drugs (Epub ahead of print.
<https://doi.org/10.1007/s10637-012-9865-z>
18. , K. L., Lee, P. W. (2005) Not all viruses are bad guys: the case for reovirus in cancer therapy. Drug Discov. Today 10, 847-855.
<https://doi.org/10.1016/S1359-6446(05)03483-5>
19. , S. M., Holm, G. H., Pierce, J. M., Tian, B., Watson, M. J., Chari, R. S., Ballard, D. W., Brasier, A. R., Dermody, T. S. (2006) Identification of an NF-κB-dependent gene network in cells infected by mammalian reovirus. J. Virol. 80, 1077-1086.
<https://doi.org/10.1128/JVI.80.3.1077-1086.2006>
20. , M., Zhivotovsky, B. (2011) Caspases and cancer. Cell Death Differ. 18, 1441-1449.
<https://doi.org/10.1038/cdd.2011.30>
21. , T., Sauthoff, H., Huang, Y. Q., Chang, B., Cheng, J., Heitner, S., Chen, S., Rom, W. N., Hay, J. G. (2005) Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression. Gene Ther. 12, 911-917.
<https://doi.org/10.1038/sj.gt.3302459>
22. , J. P., Mottet, D., Raes, M., Michiels, C. (2002) Is HIF1α a proor an anti-apoptotic protein? Biochem. Pharmacol. 64, 889-892.
<https://doi.org/10.1016/S0006-2952(02)01155-3>
23. , C. J. (2002) Cytolytic viruses as potential anti-cancer agents. J. Gen. Virol. 83, 491-502.
<https://doi.org/10.1099/0022-1317-83-3-491>
24. , N., Cramer, T. (2011) Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist. Updat. 14, 191-201.
<https://doi.org/10.1016/j.drup.2011.03.001>
25. , G. L. (2010) HIF-1: upstream and downstream of cancer metabolism. Curr. Opin. Genet. Dev. 20, 51-56.
<https://doi.org/10.1016/j.gde.2009.10.009>
26. , A. M., Bouchier-Hayes, D. J., Condron, C. M., Toomey, D. (2003) Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat. Rev. 29, 297-307.
<https://doi.org/10.1016/S0305-7372(03)00003-3>
27. , E. A., Zhu, H., Chow, S. C., MacFarlane, M., Nicholson, D. W., Cohen, G. M. (1996) Benzyloxycarbonyl-Val-AlaAsp (OMe) fluoromethylketone (Z-VAD.FMK) inhibits apoptosis by blocking the processing of CPP32. Biochem. J. 315 (Pt 1), 21-24.
<https://doi.org/10.1042/bj3150021>
28. , N., van den Wollenberg, D. J., Borel Rinkes, I. H., Hoeben, R. C., Kranenburg, O. (2005) Sensitization to apoptosis underlies KrasD12-dependent oncolysis of murine C26 colorectal carcinoma cells by reovirus T3D. J. Virol. 79, 14981-14985.
<https://doi.org/10.1128/JVI.79.23.14981-14985.2005>
29. , E. R., Chiocca, E. A. (2000) Oncolytic viruses as novel anticancer agents: turning one scourge against another. Expert Opin. Investig. Drugs 9, 311-327.
<https://doi.org/10.1517/13543784.9.8.1841>
30. , R. E., Zweerink, H. J., Joklik, W. K. (1969) Polypeptide components of virions, top component and cores of reovirus type 3. Virology 39, 791-810.
<https://doi.org/10.1016/0042-6822(69)90017-8>
31. , J. E., Coffey, M. C., Tang, D., Sabinin, P., Lee, P. W. (1998) The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J. 17, 3351-3362.
<https://doi.org/10.1093/emboj/17.12.3351>
32. , K. L., Clarke, P., DeBiasi, R. L., Kominsky, D., Poggioli, G. J. (2001) Reoviruses and the host cell. Trends Microbiol. 9, 560-564.
<https://doi.org/10.1016/S0966-842X(01)02103-5>
33. , J. H., Kang, C. D., Bae, J. H., Shin, G. G., Kim, D. W., Kim, D. W., Chung, B. S., Kim, S. H. (2004) Association of DNA-dependent protein kinase with hypoxia inducible factor-1 and its implication in resistance to anticancer drugs in hypoxic tumor cells. Exp. Mol. Med. 36, 233-242.
<https://doi.org/10.1038/emm.2004.32>
34. , P., Kallinowski, F., Okunieff, P. (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 49, 6449-6465.
